Licensing Opportunities
The Babraham Institute aims to maximise the impact of its scientific discoveries; where appropriate this is achieved through commercialisation of its intellectual property rights. This primarily involves licensing new discoveries and technologies to pharma and biotech companies, but in some cases commercialisation is achieved through spinning-out new companies such as Crescendo Biologics Ltd.Patents
Enhancing the potency of stem cellsInternational patent applications filed in USA, Europe, Japan, Australia, Canada, China. (priority date 17th December 2012) Worldwide
Download flyer
VDJ-Seq
International patent applications filed in Europe, USA and Japan (priority date 2nd March 2012) Non-exclusive, worldwide
Download flyer
Capture Hi-C: Deciphering the 3D folding of the genome
Priority patent application filed 5th September 2013. Worldwide
Please contact us for further details.
Reagents
All reagents are available worldwide non-exclusively through Ximbio- Monoclonal antibody against 5-hydroxymethylcytosine
Ficz et al (2010) Nature 473, 398-402 - Conditional p110δ knockout mice
Rolf et al (2010) J Immunol 185(7), 4042-52 - Germline p110δ knockout mice
Clayton et al (2002) J Exp Med 196(6), 753-63 - Tau P301L knockin mice
Gilley et al (2012) Neurobiol Aging 33 621.e1-621.e15 - Nmnat2-Venus transgenic mice
Milde et al (2013) Sci Rep 3, 2567